Retinoid receptors in pancreatic cancer

Alexandr Bazhin, Tim Bleul, Markus W. Büchler & Jens Werner
Introduction: Pancreatic adenocarcinoma (PDAC) has a particularly poor prognosis with a median survival of 6 months. The standard treatment today is surgical resection and subsequent adjuvant chemotherapy. This is possible in about 20% of all patients, and results in a median survival of over 20[for full text, please go to the a.m. URL]